earnings
confidence high
sentiment positive
materiality 0.65
Fennec prelim Q4 2023 net revenue $9.2-9.7M (+41-49% QoQ); FY 2023 $20.7-21.2M
FENNEC PHARMACEUTICALS INC.
2023-FY EPS reported
-$0.60
revenue$21,252,000
- Q4 2023 net revenue expected $9.2-9.7M, up 41-49% from Q3 2023.
- Full-year 2023 net revenue expected $20.7-21.2M.
- Audited Q4 and full-year results expected on or about March 26, 2024.
- PEDMARK is first FDA-approved therapy to reduce ototoxicity risk in pediatric cisplatin patients.